Literature DB >> 12463764

Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.

Peter E Morris1, R Duncan Hite, Christopher Ohl.   

Abstract

In patients with severe sepsis, thrombin has been implicated in the interrelationship between the coagulation and inflammation pathways. Thrombin is responsible for conversion of fibrinogen to fibrin (thrombus formation). Thrombin also activates endothelial cells, white blood cells and platelets. Regulation of both the coagulation and inflammation pathways is in part through the interaction of thrombin and activated protein C. Activated protein C has particular attributes that may inhibit microvascular thrombi, promote fibrinolysis and directly dampen the pro-inflammatory aspect of infection. In patients with severe sepsis, many investigators have demonstrated an active coagulopathic state, with low protein C levels. A phase III clinical trial has now demonstrated reduced mortality in patients with severe sepsis receiving activated protein C.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12463764     DOI: 10.2165/00063030-200216060-00002

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  2 in total

Review 1.  Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Authors:  James E Frampton; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.

Authors:  Anne-Cornélie J M de Pont; Kamran Bakhtiari; Barbara A Hutten; Evert de Jonge; Margreeth B Vroom; Joost C M Meijers; Harry R Büller; Marcel Levi
Journal:  Crit Care       Date:  2005-07-21       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.